Close Menu


The firm said that its instrument business was negatively impacted by lower consumables revenues, product mix, and currency translation.

During the quarter, the firm launched two new Familion genetic tests while preparing for the potential launch of its first drug.

PGxHealth has charged Toronto Research Chemicals and Santa Cruz Biotechnology for infringement because they both market the compound apadenoson, the primary ingredient of Stedivaze, a coronary vasodilator that PGxHealth is developing for myocardial perfusion imaging.

Bio-Rad, Sungkyunkwan University, Transgenomic, and Symphogen awarded US patents.

For the second month in a row, the GWDN Index and the broader market dropped sharply. Only nine firms in the Index saw their stock price gain ground in June.

The firm will use the proceeds to develop and commercialize its lead drug for depression, fund clinical trials for it coronary vasodilator, and other things.

Despite increased spending, its full-year net loss dropped sharply due to last year's charge of $55.1 million for purchased in-process R&D.

Pairings: Jun 9, 2010


Debra Schneider

The firm's full-year revenues were up 26 percent, according to the preliminary results. It also expects to offer all remaining shares of common stock on its existing shelf registration statement.

The firm's instrument revenues grew 12 percent year over year, and it launched its KRAS test kit in Europe.


NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.

In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.